ANCA-Associated Vasculitis and Infection Risk: What to Recognize

Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a rare autoimmune disease characterized by inflammation of small blood vessels. While AAV itself poses significant health challenges, patients are also at increased risk of infection. This article explores the factors that contribute to this heightened susceptibility, the types of infections commonly seen, and current understanding of managing infection risk in individuals with AAV.

Understanding ANCA-Associated Vasculitis

AAV encompasses several related conditions, including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). These diseases involve inflammation of small and medium-sized vessels, leading to damage in various organs, most commonly the lungs, kidneys, and skin. [1]

Why are AAV Patients More Susceptible to Infection?

Several factors contribute to the increased risk of infection in individuals with AAV:

• Immunosuppressive Treatment: AAV is typically treated with immunosuppressive medications, such as corticosteroids and cyclophosphamide, to control inflammation. These drugs, while effective, weaken the immune system, making patients more vulnerable to infections.
• Disease-Related Immune Dysfunction: AAV itself disrupts normal immune function. The abnormal activation of neutrophils and the production of ANCA antibodies can impair the body’s ability to fight off pathogens.
• Organ Damage: Damage to organs like the lungs and kidneys can compromise their ability to defend against infection.
• Chronic Lung Disease: The presence of chronic lung disease, a common manifestation of AAV, significantly elevates infection risk during both the initial treatment phase (induction) and ongoing management (maintenance). [2]

Common Infections in AAV Patients

AAV patients can develop a wide range of infections, including:

• Respiratory Infections: Pneumonia, bronchitis, and influenza are common due to lung involvement and immunosuppression.
• Urinary Tract Infections: Immunosuppression and potential kidney damage increase the risk of UTIs.
• Skin and Soft Tissue Infections: Breaks in the skin or wounds can become infected.
• Opportunistic Infections: Weakened immune systems are susceptible to infections caused by organisms that typically don’t cause illness in healthy individuals, such as fungal infections or Pneumocystis jirovecii pneumonia.

Interstitial Lung Disease and Infection Risk

Interstitial lung disease (ILD) is frequently observed in AAV, particularly in patients with MPA and those who test positive for myeloperoxidase (MPO)-ANCA. [3] ILD can further compromise lung function and increase the risk of respiratory infections.

Managing Infection Risk

A multifaceted approach is crucial for minimizing infection risk in AAV patients:

• Vaccination: Patients should receive recommended vaccinations, including influenza, pneumococcal, and COVID-19 vaccines, when their immune status allows.
• Prophylactic Medications: In some cases, prophylactic medications, such as antibiotics or antifungals, may be prescribed to prevent specific infections.
• Infection Monitoring: Close monitoring for signs and symptoms of infection is essential.
• Prompt Treatment: Any suspected infection should be promptly evaluated and treated with appropriate antibiotics, antivirals, or antifungals.
• Careful Medication Management: Healthcare providers should carefully weigh the risks and benefits of immunosuppressive medications and adjust dosages as needed.

Looking Ahead

Research continues to refine our understanding of infection risk in AAV and to develop strategies for minimizing this risk. Prospective studies are needed to determine the optimal treatment approaches for AAV-ILD, including the potential role of combination therapies and individualized treatment plans. [3] By proactively addressing infection risk, healthcare providers can improve the quality of life and outcomes for individuals living with AAV.